Disarming the cavalry: targeting neutrophils to limit collateral damage in non-CF bronchiectasis

Bronchiectasis is a heterogeneous disease characterised by mucous stasis, chronic bacterial infection and neutrophilic inflammation, resulting in airway destruction and irreversible bronchial dilatation [1]. Non-cystic fibrosis bronchiectasis (NCFB) is recognised as a growing source of morbidity but with a paucity of innovative treatment options [2, 3]. Treatments to date have largely focused on inhaled antibiotics and oral macrolides to reduce bacterial infection and inflammation, as well as inhaled mucoactive therapies to reduce mucous stasis [4].